Skip to Main Content

Author Details

Nathanael S Gray
Harvard Medical School
1996
483
118
PMIDPaper TitleJournal TitlePublished Year
36117402Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.J Med Virol2023
36117402Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.J Med Virol2023
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
36826833Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.J Med Chem2023
36711754Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerability.Res Sq2023
36584631Development of potent and selective degraders of PI5P4Kγ.Eur J Med Chem2023
36824856Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.bioRxiv2023
36764756Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.Methods Enzymol2023
36877894CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.Blood2023
37237081Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.Nat Cancer2023
36658220The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.Nat Cell Biol2023
37237081Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.Nat Cancer2023
36584631Development of potent and selective degraders of PI5P4Kγ.Eur J Med Chem2023
36877894CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.Blood2023
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
36711754Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerability.Res Sq2023
36826833Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.J Med Chem2023
36764756Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.Methods Enzymol2023
36824856Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.bioRxiv2023
36658220The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.Nat Cell Biol2023
34679239Novel functions of S1P in chronic itchy and inflammatory skin diseases.J Eur Acad Dermatol Venereol2022
35839780Temporal resolution of gene derepression and proteome changes upon PROTAC-mediated degradation of BCL11A protein in erythroid cells.Cell Chem Biol2022
36300789Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.Elife2022
35512193Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ¿¿What Is Expected?J Med Chem2022
35896549Targeting transcription in heart failure via CDK7/12/13 inhibition.Nat Commun2022
35442775A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.Proc Natl Acad Sci U S A2022
36220104Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation.Cell Chem Biol2022
36007246Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.ACS Chem Biol2022
35378251Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.Bioorg Med Chem Lett2022
35688808Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.Nat Commun2022
35422503An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Nat Cancer2022
36070758Exploring the target scope of KEAP1 E3 ligase-based PROTACs.Cell Chem Biol2022
35931023Retraction Notice to: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.Cell2022
35609336The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.J Med Chem2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
36416208Development and Utility of a PAK1-Selective Degrader.J Med Chem2022
35597007Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold.Eur J Med Chem2022
35534503Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.Nat Commun2022
36466034Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.Cancer Res Commun2022
35317195Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy.Front Cell Neurosci2022
34679239Novel functions of S1P in chronic itchy and inflammatory skin diseases.J Eur Acad Dermatol Venereol2022
34675395Targeting transcription cycles in cancer.Nat Rev Cancer2022
35255496A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.Blood Adv2022
35029981Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.J Med Chem2022
34965125Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216.J Med Chem2022
35149586A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer.Cancer Res2022
34544752INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.Cancer Discov2022
35198433Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.Front Oncol2022
35512193Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ¿¿What Is Expected?J Med Chem2022
35442775A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.Proc Natl Acad Sci U S A2022
  • 1 - 50 of 966

Recommended Authors

Maria H??ggblad
Karolinska Institute
Career Start Year 2013
Number of shared co-authors 1
Phillip P Sharp
University of California san francisco
Career Start Year 2013
Number of shared co-authors 4
Reza Beheshti Zavareh
The Scripps Research Institute
Career Start Year 2008
Number of shared co-authors 2
Stephanos Ioannidis
H3 Biomedicine Inc.
Career Start Year 2008
Number of shared co-authors 7
Wenwei Lin
St. Jude Children's Research Hospital
Career Start Year 2007
Number of shared co-authors 1
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 8
Kevin Lou
Howard Hughes Medical Institute, University of California san francisco
Career Start Year 2007
Number of shared co-authors 7
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 2
Jamal C Saeh
Oncology R&D
Career Start Year 2005
Number of shared co-authors 9
Matthew Elliott
College of Life Sciences, University of Dundee
Career Start Year 2003
Number of shared co-authors 8
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 3
Luke L Lairson
The Scripps Research Institute
Career Start Year 2003
Number of shared co-authors 2
Anang A Shelat
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 9
Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 11
Edward J Hennessy
Oncology R&D
Career Start Year 2002
Number of shared co-authors 8
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 14
Nancy Su
Career Start Year 2000
Number of shared co-authors 8
Rima Al-Awar
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1999
Number of shared co-authors 8
William McCoull
Oncology R&D
Career Start Year 1999
Number of shared co-authors 7
Michael Zinda
Repare Therapeutics Inc.
Career Start Year 1998
Number of shared co-authors 10
Sharad K Verma
Johns Hopkins University
Career Start Year 1998
Number of shared co-authors 2
Monika A Davare
Oregon Health Sciences University
Career Start Year 1998
Number of shared co-authors 9
Bissan Al-Lazikani
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 14
Kate F Byth
Oncology R&D
Career Start Year 1996
Number of shared co-authors 7
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Career Start Year 1994
Number of shared co-authors 7
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 18
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 6
David Uehling
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1989
Number of shared co-authors 5
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 33
Joel Morris
National Cancer Institute
Career Start Year 1986
Number of shared co-authors 3

Collaborators

Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 42
Kenneth D Westover
University of Texas Southwestern Medical Center
Co-authored papers 27
Jianwei Che
Dana-Farber Cancer Institute
Co-authored papers 21
James E Bradner
Co-authored papers 20
David M Sabatini
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Co-authored papers 18
Peter K Sorger
Co-authored papers 17
Stefan Knapp
Institute of Pharmaceutical Chemistry, Goethe University
Co-authored papers 17
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 15
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 13
Dario R Alessi
University of Dundee
Co-authored papers 13
Sirano Dhe-Paganon
Dana-Farber Cancer Institute
Co-authored papers 12
Matthew Meyerson
Broad Institute
Co-authored papers 11
Jean J Zhao
Co-authored papers 11
Markus Warmuth
Co-authored papers 9
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 9
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 9
Thomas W Gero
Dana-Farber Cancer Institute
Co-authored papers 8
Stuart L Schreiber
Broad Institute
Co-authored papers 7
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 7
Federica Piccioni
Co-authored papers 7
Lewis C Cantley
Co-authored papers 7
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 7
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 7
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 7
Mario Niepel
Co-authored papers 6
Thomas B Sundberg
Cutaneous Biology Research Center
Co-authored papers 6
Jeremy S Caldwell
Sirna Therapeutics a former subsidiary of Merck & Co., Inc.
Co-authored papers 6
Caitlin E Mills
Co-authored papers 6
Ramnik J Xavier
Broad Institute of MIT and Harvard
Co-authored papers 6
Cyril H Benes
Co-authored papers 6
Release 1.2